Advertisement

Immunkoagulopathien

  • K. Lechner
Part of the Handbuch der Inneren Medizin book series (INNEREN, volume 2 / 9)

Zusammenfassung

Unter Immunkoagulopathien versteht man Gerinnungsstörungen, die bei vorher gerinnungsnormalen Personen auftreten und durch ein Immunglobulin mit gerinnungshemmender Wirkung bedingt sind. Gerinnungshemmende Immunglobuline werden als Inhibitoren bezeichnet und, da sie bei vorher gerin-nungsnormalen Personen auftreten, häufig als spontane Inhibitoren („spontaneous inhibitors“) bezeichnet. Im deutschen Sprachraum wird statt des Wortes Inhibitor auch häufig der Begriff Hemmstoff oder Hemmkörper verwendet und dementsprechend die dadurch hervorgerufene Gerinnungsstörung als Hemmkörperhämophilie (Deutsch 1950) bezeichnet. Sinnvollerweise wird der Ausdruck Hemmkörperhämophilie jedoch nur für F-VIII- oder F-IX-Mangelzustände reserviert bleiben, die durch spontane Inhibitoren hervorgerufen werden.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Âberg H, Nilsson IM (1972) Recurrent thrombosis in a young woman with circulating anticoagulant directed against factor XI and XII. Acta Med Scand 192: 419PubMedGoogle Scholar
  2. Al-Ismail SAD, Parry DH, Moisey CU, Bloom AL (1979) Factor VIII inhibitor and bronchogenic carcinoma. Thromb Haemost 41: 291PubMedGoogle Scholar
  3. Allain JP, Gaillandre A, Lee H (1981b) Immunochemical characterization of antibodies to factor VIII in hemophilic and nonhemophilic patients. J Lab Clin Med 97: 791PubMedGoogle Scholar
  4. Allain JP, Gaillandre A, Frommel D (1981a) Acquired hemophilia: Functional study of antibodies to factor VIII. Thromb Haemost 45: 285Google Scholar
  5. Allain JP, Croissant M, Lerolle D et al (1982) In vivo interactions of autoantibodies to factor VIII with the factor VIII complex. Thromb Haemost 48: 142PubMedGoogle Scholar
  6. Amblard P, Reymond JL, Beani JC (1981) Anticoagulants acquis d’origine immunologique: Association d’une pemphigoide localisee et d’un anticoagulant anti-facteur VIII. Nouvelle Presse Med 31: 2484–2585Google Scholar
  7. Ardeman S, Boralessa H, Sale RJ (1981) Coagulation inhibitor in hypothyroidism. Br Med J 282: 1508Google Scholar
  8. Bajaj SP, Rapaport SI, Barclay SJ, Herbst KD (1983 a) Acquired prothrombin deficiency in the absence of the “lupus anticoagulant”: Demonstration of an antibody that does not neutralize prothrombin clotting activity in vitro. Thromb Haemost 50:345 (abstr)Google Scholar
  9. Bajaj SP, Rapaport SI, Fierer DS (1983 b) A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome. Blood 61: 684Google Scholar
  10. Beck D, Strauss R et al (1979) An intrinsic coagulation pathway inhibitor in a 3-year-old child. Am J Clin Pathol 71: 470PubMedGoogle Scholar
  11. Boffa MC, Horellou MH, Wiesel ML (1983) Lupus and Lupus-type anticoagulants: Two groups distinguished by vipera berus phospholipase. Thromb Haemost 50: 345Google Scholar
  12. Bowie EW, Thompson JH, Pascuszzi CA, Owen CA (1963) Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med 62: 416PubMedGoogle Scholar
  13. Brockhaus W, Lechner K (1978) Studies in a patient with a spontaneous inhibitor against factor V. XVII. Congress Int Soc Hematology, Paris ( Abstr) International Society of Blood Transfusion, Book of Abstracts, p 516Google Scholar
  14. Brodeur GM, O’Neill PJ, Wilimas JA (1980) Acquired inhibitors of coagulation in nonhemophilic children. J Pediatr 96:439 Bryning K, Leslie J ( 1977 ) Factor V inhibitor and bullous pemphigoid. Br Med J ii: 677Google Scholar
  15. Canciani MT, Maspero ML, Cattaneo M, Mannucci PM (1979) Clinical and laboratory observations in eight patients with lupus-type circulating anticoagulant. Haematologica 64: 316Google Scholar
  16. Canoso RT, Hutton RA (1977) A chlorpromazine-induced inhibitor of blood coagulation. Am J Hematol 2: 183PubMedGoogle Scholar
  17. Canoso RT, Sise HS (1982) Chlorpromazine-induced lupus anticoagulant and associated immunologic abnormalities. Am J Hematol 13: 121PubMedGoogle Scholar
  18. Carreras LO, Machin SJ, Deman R (1981) Arterial thrombosis, intrauterine death and “lupus” anticoagulant. Detection of immunoglobulin interfering with prostacyclin formation. Lancet 1: 244Google Scholar
  19. Castaldi PA, Penny R (1970) A macroglobulin with inhibitory activity against coagulation factor VIII. Blood 35: 370PubMedGoogle Scholar
  20. Castro O, Farber LR, Clyne LP (1972) Circulating anticoagulants against factors IX and XI in systemic lupus erythematosus. Ann Intern Med 77: 543PubMedGoogle Scholar
  21. Chediak J, Ashenhurst JB, Garick I, Desser RK (1980) Successful management of bleeding in a patient with factor V inhibitor by platelet transfusions. Blood 56: 835PubMedGoogle Scholar
  22. Clyne LP, Dainiak N, Hoffman R, Hardin J (1980) In vitro correction of anticoagulant activity and specific clotting factor assays in SLE. Thromb Res 18: 643PubMedGoogle Scholar
  23. Coller B, Hultin M, Hoyer et al (1981) Normal pregnancy in a patient with a prior postpartum factor VIII inhibitor: with observations on pathogenesis and prognosis. Blood 58: 619PubMedGoogle Scholar
  24. Cooper MR, Cohen JH, Huntley CC et al (1974) A monoclonal IgM with antibodylike specificity for phospholipids in a patient with lymphoma. Blood 43: 493PubMedGoogle Scholar
  25. Coots MC, Muhleman AF, Glueck HI (1978) Hemorrhagic death associated with a high titer factor V inhibitor. Am J Hematol 4: 193PubMedGoogle Scholar
  26. Coots MC, Miller MA, Glueck HI (1981) The lupus inhibitor: A study of its heterogeneity. Thromb Haemost 46: 734Google Scholar
  27. Corrigan J J (1970) Incoagulability of blood in systenic lupus erythematosus. A case due to hypopro-thrombinemia and a circulating anticoagulant. Am J Dis Child 119: 365PubMedGoogle Scholar
  28. Criel A, Collen D, Masson PL (1978) A case of IgM antibodies which inhibit the contact activation of blood coagulation. Thromb Res 12: 883PubMedGoogle Scholar
  29. Cronberg S, Nilsson IM (1973) Circulating anticoagulant against factors XI and XII together with massive spontaneous platelet aggregation. Scand J Haematol 10: 309PubMedGoogle Scholar
  30. Dahlbäck B, Nilsson IM, Frohm B (1983) Inhibition of platelet prothrombinase activity by a lupus anticoagulant. Blood 1: 218Google Scholar
  31. Davis RB, Krueger JA, Loomis GW (1979) Membranous glomerulonephritis with a circulating inhibitor of factor XI. Thromb Haemost 42: 24 (abstr)Google Scholar
  32. Deutsch E (1950) Über eine eigentümliche hämorrhagische Diathese: die Hemmkörperhämophilie. Klin Wochenschr 28: 326PubMedGoogle Scholar
  33. Devereux S, Fisher DM, Roter BLT, Hegde UM (1983) Factor VIII inhibitor and raised platelet IgG levels associated with a-methyldopa therapy. Br J Haematol 54: 485PubMedGoogle Scholar
  34. Duran-Suarez JR, Triginier J (1982) Aspectos clinico-biologicos de las antiprotrombinasas. Sangre 27: 994PubMedGoogle Scholar
  35. Duran-Suarez JR, Vilaseca J, Ordeig J, Triginer J (1981) Anticoagulante circulante dirigido contra el factor XI. Sangre 26: 631PubMedGoogle Scholar
  36. Duran-Suarez JR, Villa M, Rodriguez Bueno S, Triginer J (1982) Circulating anticoagulant against factor XII in smoldering leukemia. Acta Haemat (Basel) 67: 128Google Scholar
  37. Edson RJ, Vogt JM, Hasegawa DK (1984) Abnormal prothrombin crossed-immunoelectrophoresis in patients with lupus inhibitors. Blood 64: 807PubMedGoogle Scholar
  38. Eldor A, Elias M (1983) Thromboembolic events in patients with “lupus” type anticoagulant. Thromb Haemost 50: 345Google Scholar
  39. Erskine JG, Burnett AK, Walker ID, Davidson JF (1981) Plasma exchange in non-haemophiliac patients with inhibitors to factor VIIIC. Br Med J 283: 760Google Scholar
  40. Exner T, Rickard KA, Kronenberg H (1978) A sensitive test demonstrating lupus anticoagulant and its behavioural patterns. Br J Haematol 40: 143PubMedGoogle Scholar
  41. Exner T, Barber S, Kronenberg H, Rickard KA (1980) Familial association of the lupus anticoagulant. Br J Haematol 45: 89PubMedGoogle Scholar
  42. Feinstein DI (1978) Acquired inhibitors of factor V. Thromb Haemost 39: 663PubMedGoogle Scholar
  43. Firkin BG, Howard MA, Radford N (1980) Possible relationship between lupus inhibitor and recurrent abortion in young women. Lancet II: 366Google Scholar
  44. Follea G, Coiffier B, Viale JP, Dechavanne MD (1981) Antiprothrombinase and factor II deficiency in a non SLE patient. Thromb Haemost 46: 670PubMedGoogle Scholar
  45. Galanakis DK, Ginzier EM, Fikrig SM (1978) Monoclonal IgG anticoagulants delaying fibrin aggregation in two patients with systemic lupus erythematosus. Blood 52: 1037PubMedGoogle Scholar
  46. Gandolfo G, Afeltra A, Amoroso A et al (1977) Circulating anticoagulant against factor XII and platelet antibodies in systemic lupus erythematosus. Acta Haematol 57: 135PubMedGoogle Scholar
  47. Gawryl MS, Hoyer LW (1982) Inactivation of factor VIII coagulant activity by two different types of human antibodies. Blood 60: 1103PubMedGoogle Scholar
  48. Ghosh S, McEvoy P, McVerry BA (1983) Idiopathic autoantibody that inhibits fibrin monomer polymerization. Br J Haematol 53: 65PubMedGoogle Scholar
  49. Glazier RL, Crowell EB Jr (1977) Factor VIII inhibitor associated with chlorpromazine-induced hepatic injury. Thromb Haemost 37: 523PubMedGoogle Scholar
  50. Glueck HI, Hong R (1965) A circulating anticoagulant y 1A multiple myeloma: its modification by penicillin. J Clin Invest 44: 1866PubMedGoogle Scholar
  51. Godal HC, Ly B (1977) An inhibitor of activated factor XIII, inhibiting fibrin cross-linking but not incorporation of amine into casein. Scand J Haematol 19: 443PubMedGoogle Scholar
  52. Grace CS, Wolf P (1975) A high-titer circulatory inhibitor of human factor V: clinical, biochemical and immunologic features and its treatment by plasmapheresis. Thromb Diathes Haemorrh 34: 322Google Scholar
  53. Graham J, Yount WJ, Roberts HR (1973) Immunochemical characterisation of a human antibody to factor XIII. Blood 41: 661PubMedGoogle Scholar
  54. Green D (1968) Spontaneous inhibitors of factor VIII. Br J Haematol 15: 57Google Scholar
  55. Green D (1971) Suppression of an antibody to factor VIII by a combination of factor VIII and cyclophosphamide. Blood 37: 381PubMedGoogle Scholar
  56. Green D, Lechner K (1981) A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemost 45: 200PubMedGoogle Scholar
  57. Green D, Hougie C, Kazmier FJ (1983) Report of the working party on acquired inhibitors of coagulation: Studies of “lupus” anticoagulant. Thromb Haemost 49: 144Google Scholar
  58. Handorf CR, Ricardo MJ Jr, White FL (1981) An IgM circulating anticoagulant associated with small cell carcinoma of the lung. Thromb Haemost 46: 139Google Scholar
  59. Hedner U, Nilsson IM (1976) Acquired anticoagulants against factors XI and XII in patients with severe thrombotic disease. 16th Intern Congr Haematol 88 (abstr)Google Scholar
  60. Herbst KD, Rapaport SI, Kenoyer DG et al (1981) Syndrome of an acquired inhibitor of factor VIII responsive to cyclophosphamide and prednisone. Ann Intern Med 95: 575PubMedGoogle Scholar
  61. Hoots WK, Carrell NA, Wagner RH et al (1981) A naturally occurring antibody that inhibits fibrin polymerization. N Engl J Med 304: 857PubMedGoogle Scholar
  62. Howard MA, Firkin BG (1983) Investigations of the lupus-like inhibitor by-passing activity of platelets. Thromb Haemost 50: 775PubMedGoogle Scholar
  63. Hultin MB, Shapiro SS, Bowman HS et al (1976) Immunosuppressive therapy of factor VIII inhibitors. Blood 48: 95PubMedGoogle Scholar
  64. Kasper CK, Aledort LM, Counts RE et al (1975) A more uniform measurement of factor VIII inhibitor. Thromb Diathes Haemorrh 34: 869Google Scholar
  65. Kelsey PR, Leyland HJ (1982) Acquired inhibitor to human factor VIII associated with paraproteinemia and subsequent development of chronic lymphatic leukemia. Br Med J 285: 174Google Scholar
  66. Klein KG, Parkin JD, Madaras F (1976) Studies of an acquired inhibitor of factor VIII induced by penicillin allergy. Clin Exp Immunol 26: 155PubMedGoogle Scholar
  67. Krieger H, Leddy JP, Breckenridge RT (1975) Studies on a circulating anticoagulant in systemic lupus erythematosus. Evidence for inhibition of the function of activated plasma thromboplastin anticedent (factor XIa). Blood 46: 186Google Scholar
  68. Lafer EM, Rauch J, Andrezejewski C et al (1981) Polyspecific monoclonal lupus antoantibodies against polynucleotides and phospholipids. J Exp Med 153: 897PubMedGoogle Scholar
  69. Lane TA, Shapiro SS, Burka ER (1978) Factor V antibody and disseminated intravascular coagulation. Ann Intern Med 89: 182PubMedGoogle Scholar
  70. Largo R, Sigg P, Feiten A von, Straub PW (1974) Acquired factor IX inhibitor in a nonhaemophilic patient with autoimmune disease. Br J Haematol 26: 129PubMedGoogle Scholar
  71. Lechner K (1969) A new type of coagulation inhibitor. Thromb Diath Haemorrh 21: 482PubMedGoogle Scholar
  72. Lechner K (1971) Acquired inhibitors in iso-and auto-immune disease. Thromb Diath Haemorrh [Suppl] 45: 227Google Scholar
  73. Lechner K (1974) Acquired inhibitors in non-haemophilic patients. Haemost 3: 65Google Scholar
  74. Lechner K, Korninger Ch (1981) Structure, characteristics and natural history of factor VIII-and IX-inhibitors in non-hemophiliacs. Castle House Publications, London, p 87Google Scholar
  75. Lechner K, Krinninger B (1978) Immunkoagulopathien: Pathogenese, Diagnostik und Therapie. In: Heene DL (Hrsg) Immunologische Probleme in der Blutgerinnung, von Willebrand-Syndrom. Schattauer, Stuttgart New York, S 78Google Scholar
  76. Lechner K, Fischer M, Kühböck J et al (1969) Über einen Hemmkörper der Prothrombinaktivierung. Klin Wochenschr 47: 1225PubMedGoogle Scholar
  77. Leone G, Accorra F, Boni P (1977) Circulating anticoagulant against factor XI and thrombocytopenia with platelet aggregation inhibition in systemic lupus erythematosus. Acta Haematol (Basel) 58: 240Google Scholar
  78. Levy G, Juhan I, Calas-Ailland M et al (1980) Apparation d’un inhibitor du facteur VIII. Ann Anesth Franc 5: 545Google Scholar
  79. Loeliger A (1959) Prothrombin as co-factor of the circulating anticoagulant in systemic lupus erythem-atosus. Thromb Diath Haemorrh 3: 237Google Scholar
  80. Lewis JH, Szeto IL, Ellis LD et al (1967) An acquired inhibitor to coagulation factor XIII. Johns Hopkins Med J 120: 401PubMedGoogle Scholar
  81. Long LA, Riopelle JL, Francoeur M (1955) Macroglobulinemia. Effect of macroglobulins on prothrombin conversion accelerators. Can Med Assoc J 73: 726Google Scholar
  82. Lopaciuk S, Bykowska K, McDonagh JM et al (1978) Differences between type I autoimmune inhibitors of fibrin stabilization in two patients with severe hemorrhagic disorder. J Clin Invest 61: 1196PubMedGoogle Scholar
  83. Lorand L, Maldonado N, Fradera I et al (1972) Haemorrhagic syndrome of autoimmune origin with a specific inhibitor against fibrin stabilizing factor (factor XIII). Br J Haematol 23: 17PubMedGoogle Scholar
  84. Lorand L, Jacobsen A, Bruner-Lorand J (1968) A pathological inhibitor of fibrin crosslinking. J Clin Invest 47: 268PubMedGoogle Scholar
  85. Lorand L, Losowsky MS, Miloszewski K (1980) Human factor XIII fibrin-stabilising factor. Prog Hemost Thromb 5: 245PubMedGoogle Scholar
  86. Mammen EF, Schmidt KP, Barnhart MI (1967) Thrombophlebitis migrans associated with circulating antibodies against fibrinogen. Thromb Diath Haemorrh 18: 605PubMedGoogle Scholar
  87. Manoharan A, Gibson L, Rush B, Feery BO (1977) Recurrent venous thrombosis with a “lupus” coagulation inhibitor in the absence of systemic lupus. Aust NZ J Med 7: 422Google Scholar
  88. Marciniak E, Greenwood MF (1979) Acquired inhibitor delaying fibrinopeptide release. Blood 53: 81PubMedGoogle Scholar
  89. Marmont A (1969) Autoimmune coagulopathy of an antifactor IX (PTC) antibody. Description of a case and review of the literature. Its treatment with immunsuppressive agents. Fol Allerg 16: 13Google Scholar
  90. McDevitt NB, McDonagh J, Taylor HL, Roberts HP (1972) An acquired inhibitor to factor XIII. Arch Intern Med 130: 772PubMedGoogle Scholar
  91. McKelvey EM, Kwaan HC (1972) An IgM circulating anticoagulant with factor VIII inhibitory activity. Ann Intern Med 77: 571PubMedGoogle Scholar
  92. McLellan SL, Hussey CV, Fobian JE, Pisciotta AV (1981) Kinetics of factor VIII inhibitors in three non-hemophilliac patients. Thromb Haemost 46: 332Google Scholar
  93. Michiels JJ, Bosch LJ, Pias PM van der, Abels J (1978) Factor VIII inhibitor postpartum. Scand J Haematol 20: 97PubMedGoogle Scholar
  94. Miller K, Neely JE, Krivit W, Edson JR (1978) Spontaneously acquired factor IX inhibitor in a nonhemophilic child. J Pediatr 93: 232PubMedGoogle Scholar
  95. Milner GR, Holt PJL, Bottomley J, Maclver JE (1977) Practolol therapy associated with a systemic lupus erythematosus-like syndrome and an inhibitor to factor XIII. J Clin Pathol 30: 770PubMedGoogle Scholar
  96. Mueh JR, Herbst KD, Rapaport, Kenneth D (1980) Thrombosis in patients with the lupus anticoagulant. Ann Intern Med 92: 156PubMedGoogle Scholar
  97. Nakasmima K, Miyahara T, Fujil S et al (1982) Spontaneously acquired factor VIII inhibitor in a 7 year old girl. Acta Haematol 68: 58Google Scholar
  98. Natelson EA, Cyprus GS, Hettig RA (1976) Absent factor II in systemic lupus erythematosus. Arthritis Rheum 19: 79PubMedGoogle Scholar
  99. Nilsson IM, Astedt B, Hedner U, Berezin D (1975) Intrauterine death and circulating anticoagulant (“antithromboplastin”). Acta Med Scand 197: 153PubMedGoogle Scholar
  100. O’Reilly RA, Hamilton RD et al (1980) Acquired hemophilia, meningioma and diphenylhydantoin therapy. J Neurosurg 53 /5: 600PubMedGoogle Scholar
  101. Orris DJ, Lewis JH, Spero JA, Hasiba V (1980) Blocking coagulation inhibitors in children taking penicillin. J Pediatr 97: 426PubMedGoogle Scholar
  102. Otis PT, Feinstein DI, Rapaport SI, Patch MJ (1974) An acquired inhibitor of fibrin stabilization associated with isoniazid therapy: clinical and biochemical observations. Blood 44: 771PubMedGoogle Scholar
  103. Özsoylu S, Özer F (1973) Acquired Factor IX deficiency. Acta Haematol 50: 305PubMedGoogle Scholar
  104. Peck B, Hoffman GS, Franck WA (1978) Thromboplebitis in systemic lupus erythematodes. JAMA 240: 128Google Scholar
  105. Poon Man-Chiu, Saito M, Ratnoff OD et al (1977) Techniques for demonstration of the specificity of circulating anticoagulants against antithemophilic factor (factor VIII), with studies of two cases possibly related to diphenylhydantoin therapy. Blood 49: 477Google Scholar
  106. Priluck I, Howe R, Eifrig D et al (1978) Retinal surgery complicated by a spontaneously acquired factor VIII inhibitor. Am J Ophthalmol 86: 27PubMedGoogle Scholar
  107. Ratnoff OD, Salah R (1978) Autologous antibodies to AHF and phenytoin. Blood 51: 768PubMedGoogle Scholar
  108. Raz I, Rimon A, Lahay M (1975) Inhibition of blood coagulation factor XI-XII by monoclonal IgM. Isr J Med Sei 11: 1392 (Abstract)Google Scholar
  109. Regan MG, Lackner H, Karpatkin S (1974) Platelet function and coagulation profile in lupus erythematosus. Studies in 50 patients. Ann Intern Med 81: 462PubMedGoogle Scholar
  110. Rivard GE, Schiffman S, Rapaport SI (1974) Cofactor of the “lupus anticoagulant”. Thromb Diath Haemorrh 32: 554PubMedGoogle Scholar
  111. Rosenberg RD, Coman RW, Lorand L (1974) A new haemorrhagic disorder with defective fibrin stabilization and cryoflbrinogenaemia. Br J Haematol 26: 269–28PubMedGoogle Scholar
  112. Sanchez-Medal L, Lisker R, Lopes E (1963) Unusual circulating anticoagulant in a patient with systemic lupus erythematosus. Acta Haematol 29: 117PubMedGoogle Scholar
  113. Schlieder MA, Nachman RL, Jaffe EA, Coleman M (1976) A clinical study of the lupus anticoagulant. Blood 48: 499Google Scholar
  114. Scully MF, Ellis V, Kakkar VV et al (1982) An acquired coagulation inhibitor to factor II. Br J Haematol 50: 655PubMedGoogle Scholar
  115. Shapiro SS (1979) Antibodies to blood coagulation factors. Clin Haematol 8: 207PubMedGoogle Scholar
  116. Shapiro SS, Hultin M (1975) Acquired inhibitors to the blood coagulation factors. Semin Thromb Hemost 1: 336Google Scholar
  117. Sherman LA, Goldstein MA, Sise HS (1969) Circulating anticoagulant (anti-factor VIII) treated with immunsuppressive drugs. Thromb Diath Haemorrh 21: 249PubMedGoogle Scholar
  118. Soulier JP, Boffa MC (1980) Avortments a repetition, thromboses et anticoagulant circulant anti-thromboplastine. Nouv Presse Med 9: 859Google Scholar
  119. Spero JA, Lewis JH, Hasiba U (1981) Corticosteroid therapy for acquired F VIII:C inhibitors. Br J Haematol 48: 635PubMedGoogle Scholar
  120. Stenbjerg S, Husted S, Mygind K et al (1975) A circulating factor V inhibitor: possible side effect of treatment with streptomycin. Scand J Haematol 14: 280PubMedGoogle Scholar
  121. Sultan Y, Maisonneuve P et al (1983) Successful management of a patient with an acquired factor VIII inhibitor. Transfusion 23: 62PubMedGoogle Scholar
  122. Thiagarajan P, Shapiro SS, Marco L de (1980) Monoclonal immunoglobulin M coagulation inhibitor with phospholipid specificity. J Clin Invest 66: 397PubMedGoogle Scholar
  123. Torres A, Bosch N, Fonseca G, Rodriguez A (1980) Estudio sobre un inhibidor de la coagulacion con marcado efecto anti-XIa en un caso de lupus eritematoso diseminado. Sangre 25: 404Google Scholar
  124. Vera JC, Herzig EB, Sise HS, Brauer MJ (1975) Acquired circulating anticoagulant to factor VIII. Response to high doses of cryoprecipitate and immunosuppressive therapy. JAMA 232: 1038Google Scholar
  125. Voke J, Letsky E (1977) Pregnancy and antibody to factor VIII. J Clin Pathol 30: 928PubMedGoogle Scholar
  126. Waddell CC, Lehane DE, Zubler MA et al (1981) Acquired factor VIII inhibitor in a patient with mycosis fungoides. Cancer 47: 2901PubMedGoogle Scholar
  127. Wenz B, Friedman G (1974) Acquired factor VIII inhibitor in a patient with malignant lymphoma. Am J Med Sei 268: 295Google Scholar
  128. Williams H, Laurent R, Gibson T (1980) The lupus coagulation inhibitor and venous thrombosis: a report of four cases. Clin Lab Haematol 2: 139PubMedGoogle Scholar
  129. Yin ET, Gaston LW (1965) Purification and kinetic studies on a circulating anticoagulant in a suspected case of lupus erythematosus. Thromb Diath Haemorrh 14: 88PubMedGoogle Scholar
  130. Zucker ST, Zerrabi MH, Romano GS, Miller F (1978) IgM inhibitors of the contact activation phase of coagulation in chlorpromazine-treated patients. Br J Haematol 40: 447–457PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1985

Authors and Affiliations

  • K. Lechner

There are no affiliations available

Personalised recommendations